行情

PCRX

PCRX

PACIRA制药
NASDAQ

实时行情|Nasdaq Last Sale

32.63
+0.63
+1.97%
盘后: 32.63 0 0.00% 16:24 04/07 EDT
开盘
33.15
昨收
32.00
最高
35.28
最低
32.50
成交量
91.29万
成交额
--
52周最高
51.35
52周最低
27.46
市值
13.72亿
市盈率(TTM)
-122.7153
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PCRX价格均价为56.23,最高价位85.00,最低价为44.00。

EPS

PCRX 新闻

更多
  • Is Pacira Pharmaceuticals Inc (PCRX) Going to Burn These Hedge Funds?
  • Insider Monkey · 2小时前
  • Northland Capital Markets Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target to $50
  • Benzinga · 7小时前
  • How This Top Fund Manager Seeks Stocks That Benefit From The Coronavirus Stock Market
  • Investor's Business Daily · 1天前
  • FDA accepts Innocoll application for post-surgical pain implant
  • Seeking Alpha - Article · 03/26 17:10

所属板块

制药
-0.19%
制药与医学研究
-0.82%

热门股票

代码
价格
涨跌幅

PCRX 简况

Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
展开

微牛提供Pacira Biosciences Inc(NASDAQ-PCRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PCRX股票新闻,以帮助您做出投资决策。